Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 9/20 | 0.51 |
| ▸ | BCHE | P06276 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132718 | 0.88 | KEAP1 (0.51) | KEAP1NFE2L2ACHEBCHEL3MBTL1 | |
| SCHEMBL12868786 | 0.87 | FFAR4 (0.54) | L3MBTL1HTTSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL682767 | 0.87 | MAPT (0.49) | L3MBTL1SMN1; SMN2MAPTMAPK1TDP1 | |
| SCHEMBL15763278 | 0.84 | KEAP1 (0.48) | KEAP1NFE2L2L3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL24726468 | 0.84 | MAOB (0.48) | ACHEBCHEL3MBTL1HTTSMN1; SMN2 | |
| SCHEMBL12738664 | 0.83 | NPC1 (0.55) | BCHEHTTSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14200018 | 0.83 | MAPT (0.45) | L3MBTL1SMN1; SMN2MAPTMAPK1TDP1 | |
| SCHEMBL17833745 | 0.83 | SMPD1 (0.53) | ACHEBCHEHTTSMN1; SMN2MAPK1 | |
| SCHEMBL14200029 | 0.82 | MAOB (0.52) | — | |
| SCHEMBL14200152 | 0.82 | ACHE (0.47) | KEAP1NFE2L2ACHEBCHEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9879023-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879023-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9464096-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9006229-B2 | Benzothiazole compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088554-A1 | THERAPEUTIC COMPOUNDS | FURIN, NFATC1, NPC1 | KEAP1 1736/4885NFE2L2 3374/4885ACHE 4284/4885 |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | KEAP1 818/4885NFE2L2 2001/4885ACHE 849/4885 |
| US-20140045818-A1 | BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FURIN, NFATC1, RUNX1 | KEAP1 2115/4885NFE2L2 2221/4885ACHE 4391/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | KEAP1 3335/4885NFE2L2 2293/4885ACHE 3621/4885 |
| US-20160024104-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, NPC1 | KEAP1 1675/4885NFE2L2 3335/4885ACHE 4327/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | KEAP1 818/4885NFE2L2 2001/4885ACHE 849/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | KEAP1 818/4885NFE2L2 2001/4885ACHE 849/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | KEAP1 3335/4885NFE2L2 2293/4885ACHE 3621/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | KEAP1 3184/4885NFE2L2 3273/4885ACHE 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.